Acetaminophen hepatoxicity: What do we know, what don’t we know, and what do we do next?†
Open accessThe DOI matches its Crossref record.
Abstract
Acetaminophen (APAP) is a widely used analgesic that can be found alone and in combination with other medications in more than 100 over-the-counter preparations and numerous prescription medications, particularly in combination with opiates. When taken in overdose, either as a suicidal gesture, or with therapeutic intent, severe liver injury and acute liver failure can occur. Despite a massive experimental literature, the detailed understanding of the mechanism of acetaminophen's toxic effect remains in some aspects controversial and in other aspects unclear. A small fraction of a dose of acetaminophen is converted, mainly by CYP2E1, to the electrophilic metabolite N-acetyl-p-quinoneimine. This metabolite is detoxified by preferential binding to glutathione (GSH) in hepatocytes despite the greater abundance of protein-SH, which suggests that the reaction with GSH is enzymatically catalyzed by GSH S-transferases. When sufficient toxic metabolite is generated to deplete nearly completely all the cytosol and mitochondrial GSH, liver injury follows.1 However, controversy exists as to whether the profound GSH depletion itself is toxic by unmasking oxidative stress (i.e., loss of defense against endogenous reactive species even normally produced by mitochondria) or whether the reactive metabolite attacks critical protein thiols (particularly in mitochondria), which leads to loss of function and cell death. Clearly, at the very least, profound GSH depletion and covalent binding are signs of a toxic exposure level of N-acetyl-p-quinoneimine, and this situation precedes and is a necessary prerequisite for the development of toxicity. But GSH depletion and covalent binding may not be sufficient, at least on the basis of studies in animal models, which suggest that the progression and severity of the injury in vivo depends upon the interplay of other factors, both within and outside of hepatocytes. APAP, acetaminophen; GSH, glutathione; ALF, acute liver failure. A number of factors determine the dose of APAP required to reach the toxic threshold (full GSH depletion and protein adducts) and include the levels of CYPE1, the baseline levels of GSH in cytosol and mitochondria, the capacity to upregulate the generation of GSH once its consumption begins, and the capacity to sulfate and glucuronidate APAP.1, 2 These factors are under the control of known or potential genetic and environmental influences. Therefore, the dose of acetaminophen that will lead to an individual patient crossing the threshold, as evidenced by covalent binding, is highly variable and unpredictable. Furthermore, adding to the complexity of our understanding of APAP toxicity is the response of the regenerative/repair process as well as the participation of the innate immune system. Table 1 provides a list of experimental circumstances that have lead to increased or decreased susceptibility to APAP in vivo in rodent models. In most of the studies involving cytokines, chemokines, and the innate immune system, susceptibility to liver injury was altered without a change in APAP metabolism, as reflected in the extent of GSH depletion and covalent binding. Thus, aside from a massive bioenergetic catastrophe at huge doses of APAP, the metabolism of APAP in hepatocytes simultaneously leads to sensitization to the toxicity of the innate immune system and activates a "battle" between injurious and protective factors external to hepatocytes. The outcome of the battle depends on genetic and environmental influences on this delicate balance. Two accompanying "Sounding Board" articles deserve comment. Dr. Lee finds that >50% of acute liver failure(ALF) in his multicenter surveillance study is due to APAP.3 The majority of cases appear to be "unintentional" with a median dose of 34 g (taken over 3 days). Many were taking opiate combinations. Incidentally, older work has suggested that central effects of opiate agonists promote hepatic glutathione depletion4; this issue has not been addressed in humans. Dr. Lee's group has employed a simple and logical approach to confirm APAP toxicity, namely the detection of N-acetyl-p-quinoneimine-cysteine protein adducts derived from plasma proteins after dialysis and proteolysis of the plasma polypeptides.5 The detection of these protein adducts released into the circulation from the injured liver indicates unequivocally that the toxic threshold has been crossed (at least in a subpopulation of hepatocytes) and is therefore a prerequisite for toxicity. This technique can reliably verify the plausibility of APAP toxicity. Interestingly, preliminary results indicated that 20% of indeterminate cases of ALF had these adducts, showing that history is often unreliable (patient or physician?) and that APAP toxicity is probably being significantly underestimated. Also detectable blood levels of APAP were found in some ALF patients with acute viral hepatitis; these patients had worse biochemical parameters. This preliminary finding is ex
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
EASL Clinical Practice Guidelines: Drug-induced liver injury
Andrade, R. J., Aithal, G. P., Björnsson, E. S., Kaplowitz, N., Kullak-Ublick, G. A., Larrey, D., & Karlsen, T. H. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.02.014 · Cited by 1,276
Self-citationIdiosyncratic drug hepatotoxicity
Kaplowitz, N. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1750 · Cited by 1,054
Self-citationAcetaminophen-induced hepatotoxicity in mice is dependent on Tlr9 and the Nalp3 inflammasome
Imaeda, A. B., Watanabe, A., Sohail, M. A., Mahmood, S., Mohamadnejad, M., Sutterwala, F. S., Flavell, R. A., & Mehal, W. Z. (2009) · Journal of Clinical Investigation · doi:10.1172/jci35958 · Cited by 607
Larson, A. M. (2007) · Clinics in Liver Disease · doi:10.1016/j.cld.2007.06.006 · Cited by 451
Yang, W., Tao, Y., Wu, Y., Zhao, X., Ye, W., Zhao, D., Fu, L., Tian, C., Yang, J., He, F., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09046-8 · Cited by 367
Metadata
- Authors
- Kaplowitz, N.
- Venue
- Hepatology
- Published
- 2004-07
- Volume
- 40
- Issue
- 1
- Pages
- 23-26
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2043101466
- Cited by
- 142
- References
- 0
- FWCI
- 7.22
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Acetaminophen hepatoxicity: What do we know, what don’t we know, and what do we do next?†. https://app.cochat.ai/papers/10.1002/hep.20312
- The paper
- Kaplowitz, N. (2004). Acetaminophen hepatoxicity: What do we know, what don’t we know, and what do we do next?†. Hepatology. https://doi.org/10.1002/hep.20312
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.